Market Overview:
The global systemic sclerosis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of systemic sclerosis, rising awareness about available treatment options, and growing investments by key players in research and development (R&D) activities. Based on type, the global systemic sclerosis drug market is segmented into ARG-201, belimumab, BL-1110, BOT-191, C-82 and others. The belimumab segment is expected to account for the largest share of the global systemic sclerosis drug market in 2018. This segment is also projected to grow at a high CAGR during the forecast period. Based on application, the global systematic sclerosis drug market is divided into hospital use, clinic use and ambulatory surgery center (ASC) use. The hospital use segment accounted for majority share of this market in 2017 and it is projected to maintain its dominance duringthe forecast period as well).
Product Definition:
A systemic sclerosis drug is a medication used to treat the symptoms of systemic sclerosis. Systemic sclerosis is a rare autoimmune disorder that affects the skin, joints, and internal organs. The goal of treatment is to reduce inflammation and improve function. Systemic sclerosis drugs may include corticosteroids, disease-modifying antirheumatic drugs (DMARDs), or biologics.
ARG-201:
ARG-201 is a drug under clinical trials for the treatment of Systemic Sclerosis. It is an investigational new drug developed by Akcea Therapeutics, Inc. The company has reported positive results from preclinical and early phase clinical trials for ARG-201 in reducing the signs and symptoms of autoimmune diseases such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus (SLE).
Belimumab:
Belimumab is a human monoclonal antibody that targets interleukin (IL) - 1 receptor subunit. IL-1R plays an important role in the pathogenesis of Systemic Sclerosis (SSc). Belimumab is under investigation for the treatment of active SSc and psoriasis. It has also shown efficacy in reducing skin lesions and improving some clinical parameters associated with this disease, such as high temperature, fatigue, and weight loss.
Application Insights:
The global systemic sclerosis drug market has been classified into hospital, clinic, ASCs and others. The hospital segment dominated the application segment in 2015 owing to the large number of patients suffering from SSc and other associated conditions visiting hospitals for treatment. Hospital based clinics have been found to be more effective than conventional medical practices in treating this condition due to better monitoring and support services provided by these centers.
Clinical trials are being conducted with a view to determining the most effective therapeutic approach for managing Systemic Sclerosis (SSc). Clinical research studies provide proof of concept that a new drug is safe & efficacious before it is introduced into routine clinical practice. Various phases of clinical trials include: 1) Pre-clinical Testing; 2) Drug Discovery; 3) Clinical Trial Testing; 4) Post-marketing Surveillance & Safety Monitoring; 5) Large Scale Clinical Trials (LSCTs).
Regional Analysis:
North America dominated the global systemic sclerosis drug market in 2017. The presence of a large number of pharmaceutical companies, availability of effective treatment methods and high healthcare expenditure are some factors responsible for its dominance. Moreover, increasing R&D activities by various pharmaceutical companies to develop novel drugs is expected to fuel the growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising geriatric population and prevalence of other chronic diseases in this region which require long term treatment with systemic anti-inflammatory drugs (corticosteroids). In addition, growing medical tourism industry due low cost & easy availability of medicines will drive regional market during forecast years.
Growth Factors:
- Increasing incidence of systemic sclerosis
- Growing awareness about systemic sclerosis
- Rising demand for systemic sclerosis drugs
- Technological advancements in the field of systemic sclerosis drug development
- Availability of government funding for research and development in the field of systemic sclerosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Sclerosis Drug Market Research Report
By Type
ARG-201, Belimumab, BL-1110, BOT-191, C-82, Others
By Application
Hospital, Clinic, ASCs, Others
By Companies
Allergan Plc, Angion Biomedica Corp., arGentis Pharmaceuticals, LLC, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Corbus pharmaceuticals, Inc., CSL Limited, Daval International Limited, Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., Fibrocell Science, Inc., GenKyoTex S.A., GlaxoSmithKline Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Sclerosis Drug Market Report Segments:
The global Systemic Sclerosis Drug market is segmented on the basis of:
Types
ARG-201, Belimumab, BL-1110, BOT-191, C-82, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, ASCs, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan Plc
- Angion Biomedica Corp.
- arGentis Pharmaceuticals, LLC
- Bayer AG
- BioLineRx, Ltd.
- BiOrion Technologies B.V.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Corbus pharmaceuticals, Inc.
- CSL Limited
- Daval International Limited
- Digna Biotech, S.L.
- F. Hoffmann-La Roche Ltd.
- Fibrocell Science, Inc.
- GenKyoTex S.A.
- GlaxoSmithKline Plc
Highlights of The Systemic Sclerosis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ARG-201
- Belimumab
- BL-1110
- BOT-191
- C-82
- Others
- By Application:
- Hospital
- Clinic
- ASCs
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Sclerosis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic sclerosis drug is a medication used to treat the symptoms of systemic sclerosis. Systemic sclerosis is a condition that causes the body's immune system to attack and damage the skin, joints, and other organs. Systemic sclerosis drugs help reduce inflammation in the body and improve blood flow.
Some of the major companies in the systemic sclerosis drug market are Allergan Plc, Angion Biomedica Corp., arGentis Pharmaceuticals, LLC, Bayer AG, BioLineRx, Ltd., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Corbus pharmaceuticals, Inc., CSL Limited, Daval International Limited, Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., Fibrocell Science, Inc., GenKyoTex S.A., GlaxoSmithKline Plc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Sclerosis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Sclerosis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Sclerosis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Sclerosis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Sclerosis Drug Market Size & Forecast, 2018-2028
4.5.1 Systemic Sclerosis Drug Market Size and Y-o-Y Growth
4.5.2 Systemic Sclerosis Drug Market Absolute $ Opportunity
Chapter 5 Global Systemic Sclerosis Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Systemic Sclerosis Drug Market Size Forecast by Type
5.2.1 ARG-201
5.2.2 Belimumab
5.2.3 BL-1110
5.2.4 BOT-191
5.2.5 C-82
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Systemic Sclerosis Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Systemic Sclerosis Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 ASCs
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Systemic Sclerosis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Systemic Sclerosis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Systemic Sclerosis Drug Analysis and Forecast
9.1 Introduction
9.2 North America Systemic Sclerosis Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Systemic Sclerosis Drug Market Size Forecast by Type
9.6.1 ARG-201
9.6.2 Belimumab
9.6.3 BL-1110
9.6.4 BOT-191
9.6.5 C-82
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Systemic Sclerosis Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 ASCs
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Systemic Sclerosis Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Systemic Sclerosis Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Systemic Sclerosis Drug Market Size Forecast by Type
10.6.1 ARG-201
10.6.2 Belimumab
10.6.3 BL-1110
10.6.4 BOT-191
10.6.5 C-82
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Systemic Sclerosis Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 ASCs
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Systemic Sclerosis Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Systemic Sclerosis Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Systemic Sclerosis Drug Market Size Forecast by Type
11.6.1 ARG-201
11.6.2 Belimumab
11.6.3 BL-1110
11.6.4 BOT-191
11.6.5 C-82
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Systemic Sclerosis Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 ASCs
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Systemic Sclerosis Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Systemic Sclerosis Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Systemic Sclerosis Drug Market Size Forecast by Type
12.6.1 ARG-201
12.6.2 Belimumab
12.6.3 BL-1110
12.6.4 BOT-191
12.6.5 C-82
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Systemic Sclerosis Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 ASCs
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Systemic Sclerosis Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Systemic Sclerosis Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Systemic Sclerosis Drug Market Size Forecast by Type
13.6.1 ARG-201
13.6.2 Belimumab
13.6.3 BL-1110
13.6.4 BOT-191
13.6.5 C-82
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Systemic Sclerosis Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 ASCs
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Systemic Sclerosis Drug Market: Competitive Dashboard
14.2 Global Systemic Sclerosis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan Plc
14.3.2 Angion Biomedica Corp.
14.3.3 arGentis Pharmaceuticals, LLC
14.3.4 Bayer AG
14.3.5 BioLineRx, Ltd.
14.3.6 BiOrion Technologies B.V.
14.3.7 Boehringer Ingelheim GmbH
14.3.8 Bristol-Myers Squibb Company
14.3.9 Corbus pharmaceuticals, Inc.
14.3.10 CSL Limited
14.3.11 Daval International Limited
14.3.12 Digna Biotech, S.L.
14.3.13 F. Hoffmann-La Roche Ltd.
14.3.14 Fibrocell Science, Inc.
14.3.15 GenKyoTex S.A.
14.3.16 GlaxoSmithKline Plc
